In patients treated with agalsidase alfa in FOS, renal and cardiac disease progression (assessed as rate of change of eGFR and LVMI, respectively), was slower than that reported previously for the natural history of the disease.17, 19. The gene discussed is GLA; the disease is heart disorder.